MedTrace Logo

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)

NCT05354453 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2023-07-03

No results posted yet for this study

Summary

This trial starts the clinical development of BI 1839100. Effects of single rising doses of BI 1389100 on safety, tolerability and pharmacokinetics will be assessed as basis for further development in patients with pulmonary fibrosis.

Conditions

  • Healthy

Interventions

DRUG

BI 1839100

BI 1839100

DRUG

Placebo

Placebo

DRUG

allyl isothiocyanate (AITC)

allyl isothiocyanate (AITC)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2023-06-14
Completion
2023-06-14

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354453 on ClinicalTrials.gov